11:05:42 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-07 Kvartalsrapport 2024-Q2
2024-06-06 Ordinarie utdelning BIOBV 0.00 EUR
2024-06-05 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-08-09 Kvartalsrapport 2023-Q2
2023-06-15 Ordinarie utdelning BIOBV 0.00 EUR
2023-06-14 Årsstämma 2023
2023-03-22 Bokslutskommuniké 2022
2022-08-10 Kvartalsrapport 2022-Q2
2022-06-16 Ordinarie utdelning BIOBV 0.00 EUR
2022-06-15 Årsstämma 2022
2022-03-09 Extra Bolagsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-08-11 Kvartalsrapport 2021-Q2
2021-04-22 Ordinarie utdelning BIOBV 0.00 EUR
2021-04-21 Årsstämma 2021
2021-02-17 Bokslutskommuniké 2020
2020-08-12 Kvartalsrapport 2020-Q2
2020-04-23 Ordinarie utdelning BIOBV 0.00 EUR
2020-04-22 Årsstämma 2020
2020-02-19 Bokslutskommuniké 2019
2019-08-14 Kvartalsrapport 2019-Q2
2019-04-25 Ordinarie utdelning BIOBV 0.00 EUR
2019-04-24 Årsstämma 2019
2019-02-20 Bokslutskommuniké 2018
2018-08-22 Kvartalsrapport 2018-Q2
2018-08-16 Extra Bolagsstämma 2018
2018-04-26 Ordinarie utdelning BIOBV 0.00 EUR
2018-04-25 Årsstämma 2018
2018-02-28 Bokslutskommuniké 2017
2017-07-27 Kvartalsrapport 2017-Q2
2017-04-27 Ordinarie utdelning BIOBV 0.00 EUR
2017-04-26 Årsstämma 2017
2017-02-02 Bokslutskommuniké 2016
2016-10-20 15-10 2016-Q3
2016-08-10 Kvartalsrapport 2016-Q2
2016-05-12 Kvartalsrapport 2016-Q1
2016-04-26 Ordinarie utdelning BIOBV 0.00 EUR
2016-04-25 Årsstämma 2016
2016-02-25 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-05-07 Kvartalsrapport 2015-Q1
2015-04-21 Ordinarie utdelning BIOBV 0.00 EUR
2015-04-20 Årsstämma 2015
2015-02-26 Bokslutskommuniké 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-08-21 Kvartalsrapport 2014-Q2
2014-05-08 Kvartalsrapport 2014-Q1
2014-04-15 Ordinarie utdelning BIOBV 0.72 EUR
2014-04-14 Årsstämma 2014
2014-02-27 Bokslutskommuniké 2013
2013-10-24 Kvartalsrapport 2013-Q3
2013-08-08 Kvartalsrapport 2013-Q2
2013-04-25 Kvartalsrapport 2013-Q1
2013-04-09 Ordinarie utdelning BIOBV 0.50 EUR
2013-04-08 Årsstämma 2013
2013-02-27 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-08-16 Kvartalsrapport 2012-Q2
2012-04-26 Kvartalsrapport 2012-Q1
2012-04-12 Ordinarie utdelning BIOBV 1.00 EUR
2012-04-11 Årsstämma 2012
2012-02-29 Bokslutskommuniké 2011
2011-11-23 Extra Bolagsstämma 2011
2011-10-20 Kvartalsrapport 2011-Q3
2011-08-18 Kvartalsrapport 2011-Q2
2011-04-28 Kvartalsrapport 2011-Q1
2011-04-14 Ordinarie utdelning BIOBV 0.00 EUR
2011-04-13 Årsstämma 2011
2011-03-01 Bokslutskommuniké 2010
2010-04-26 Ordinarie utdelning BIOBV 0.00 EUR
2009-04-21 Ordinarie utdelning BIOBV 0.00 EUR
2008-04-22 Ordinarie utdelning BIOBV 0.00 EUR
2007-04-20 Ordinarie utdelning BIOBV 0.00 EUR
2006-04-21 Ordinarie utdelning BIOBV 0.00 EUR
2005-04-22 Ordinarie utdelning BIOBV 0.00 EUR
2004-04-16 Ordinarie utdelning BIOBV 0.00 EUR
2003-04-10 Ordinarie utdelning BIOBV 0.00 EUR
2002-04-02 Ordinarie utdelning BIOBV 0.00 EUR
2001-03-28 Ordinarie utdelning BIOBV 0.00 EUR
2000-04-07 Ordinarie utdelning BIOBV 0.00 EUR
1999-04-22 Ordinarie utdelning BIOBV 0.00 EUR

Beskrivning

LandFinland
ListaSmall Cap Helsinki
SektorHälsovård
IndustriMedicinteknik
Biohit är verksamt inom medicinteknik. Bolaget utvecklar och tillverkar laboratorieutrustning, förnödenheter samt diagnostiska analyssystem anpassade för forskning, vård och industrilaboratorium. Utöver huvudverksamheten erbjuds teknisk support, underhåll samt utbildningstjänster inom nämnt arbetsområde. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget har sitt huvudkontor i Helsingfors.
2022-09-07 12:00:00

GastroPanel- availability expands substantially when Randox started the global sales of its CE-labelled  MULTIPLEX GASROINTESTINAL PANEL-test based on the Biohit license (1). Randox is a British health technology enterprise operating on global market, with the annual turnover of around 730 million euro in 2021.

GastroPanel is a diagnostic blood test developed by Biohit Oyj, detecting Helicobacter infection in the stomach, atrophic gastritis (stomach mucosal a trophy) as well as the level of gastric acid output, thus disclosing the potential risks associated with these conditions, e.g.  gastric- and esophageal cancer as well as  deficiency of vitamin-B12 and iron (2). GastroPanel does not replace endoscopic examination (gastroscopy), but as a screening- and diagnostic blood test, GastroPanel has several advantages as compared with invasive gastroscopy which is felt uncomfortable by most patients.

Quick, easy and cost-effective GastroPanel saves resources of an overloaded health care while helping in a timely referral for gastroscopy of those patients who truly need it (3). Stomach mucosal atrophy and eventually resulting gastric cancer can be diagnosed only by gastroscopy. Far too often, this happens too late, when the patient already presents with cancer-related alarming symptoms, at which stage the disease outlook is poor.  In Finland, 1016 new patients were diagnosed with gastric- and esophageal cancer in 2021, and 785 patients died of these cancers. Accordingly, clinical examination of the upper abdominal symptoms as well as screening of asymptomatic subjects at risk is of prime importance for primary prevention and early diagnosis (4). Gastric cancer is the fifth most common cancer worldwide. In Europe, it is ranking fourth among the most fatal cancers.

The multiplex version of the GastroPanel test, launched by Randox based on the Biohit license, is an excellent addition to the existing test platforms and undoubtedly increases the visibility and use of GastroPanel worldwide. Co-operation with Randox is a strong signal of the major potential of Biohit innovations.

The Biochip Array Technology (BAT) developed by Randox permits a simultaneous measurement of the three GastroPanel biomarkers (pepsinogen I, pepsinogen II and gastrin-17) in a single blood sample. When  Helicobacter pylori-test is being made from the same sample using the  same test platform, testing is extremely rapid and cost-effective.

Biohit welcomes the Randox multiplex GastroPanel into global market. 

Additional information: 
investor.relations@biohit.fi
www.biohithealthcare.com (https://eur04.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.biohithealthcare.com%2F&data=05%7C01%7CSanna.Kurlin%40biohit.fi%7C287a7a5829e5465b644a08da909dca68%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C637981304627869403%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=Rai%2FmC%2F9aUeen6VgJI2%2FnYpN4XlApFtSFTY6pPMLCzE%3D&reserved=0)

 Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is "Innovating for Health" - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com (https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3Dciyb_iZ945H2z3sK3a9i7Zs03Nkj9jr5Brw7kC1tsoUye5PVgko06PC57Z9BVVT2pXUgp6sn-tswLd2MUgQOQc8UNXD2BkNm3L02XzRJ7XfJCPaPUqGS1mpI0NZinK5T&data=05%7C01%7CSanna.Kurlin%40biohit.fi%7C287a7a5829e5465b644a08da909dca68%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C637981304627869403%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=H21OzA8Yko9zQl2CfAJLtB3rnQGCMIFcGS5FAQ9qnsI%3D&reserved=0)

References  

1.https://www.randox.com/gastrointestinal-biochip-arrays/?highlight=gastropanel (https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.randox.com%2Fgastrointestinal-biochip-arrays%2F%3Fhighlight%3Dgastropanel&data=05%7C01%7CSanna.Kurlin%40biohit.fi%7C287a7a5829e5465b644a08da909dca68%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C637981304628025629%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=1zqlMyjopMS1C9KyRTP1A1Vlr%2BvDvV%2BsMI4v74uG0j8%3D&reserved=0)

2.https://www.biohithealthcare.com/additional-information (https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.biohithealthcare.com%2Fadditional-information&data=05%7C01%7CSanna.Kurlin%40biohit.fi%7C287a7a5829e5465b644a08da909dca68%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C637981304628025629%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=%2FKnwq0Is9vozwEMJ94C73iQ%2F7ZJkfBZ1MGCC0YACHuA%3D&reserved=0)

3.https://www.biohithealthcare.com (https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.biohithealthcare.com%2F&data=05%7C01%7CSanna.Kurlin%40biohit.fi%7C287a7a5829e5465b644a08da909dca68%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C637981304628025629%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=T5DdI4vVZduIDFlgdam677mlBZvyvzRzEqeI1fXMYO8%3D&reserved=0) /News/Reading material: GastroPanel innovation (https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.biohithealthcare.com%2Fwp-content%2Fuploads%2F2020%2F04%2FGastroPanel-innovation.pdf&data=05%7C01%7CSanna.Kurlin%40biohit.fi%7C287a7a5829e5465b644a08da909dca68%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C637981304628025629%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=ZAh1PrIxyL1ilylE9UOkVgKdJ2%2FjV%2BgHnNVv8oTNWoc%3D&reserved=0)

4.https://www.biohithealthcare.com (https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.biohithealthcare.com%2F&data=05%7C01%7CSanna.Kurlin%40biohit.fi%7C287a7a5829e5465b644a08da909dca68%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C637981304628025629%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=T5DdI4vVZduIDFlgdam677mlBZvyvzRzEqeI1fXMYO8%3D&reserved=0) /Investors/Stock Exchange Releases: 2022-08-09T10:00:00Z - Dyspeptic symptoms need early attention- domestic innovations GastroPanel®, ColonView-FIT® and Acetium® will help (https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fnews.cision.com%2Fbiohit-oyj%2Fr%2Fdyspeptic-symptoms-need-early-attention--domestic-innovations-gastropanel--colonview-fit--and-acetiu%2Cc3611429&data=05%7C01%7CSanna.Kurlin%40biohit.fi%7C287a7a5829e5465b644a08da909dca68%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C637981304628025629%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=qYYvFKl5aTh4Th6IlAd1wR54ILMHSi2JdZ%2F9Q8cJB0I%3D&reserved=0)